Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples
N/A
N/A
Both
Renal Cell Carcinoma
Trial Information
Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples
Renal cancers have different clinical outcomes. The principal research objective is to study
tumour tissue from renal cancer patients and try and understand why some cancers progress
more rapidly than others. Further, another key aim of this study is to try and understand
why some patients respond to treatment and others do not.
Inclusion Criteria:
- The presence of histologically proven renal cell cancer
- The availability of paraffin embedded tissue
- Informed consent needed for tissue taken after January 2006 (date of enforcement of
human tissue act)
Exclusion Criteria:
- Absence of histological tissue
- Absence of consent to study tissue after January 2006
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes.
Safety Issue:
No
Principal Investigator
Professor Martin Gore
Investigator Role:
Principal Investigator
Investigator Affiliation:
Royal Marsden NHS Foundation Trust
Authority:
United Kingdom: Research Ethics Committee
Study ID:
CCR3076
NCT ID:
NCT01002937
Start Date:
December 2008
Completion Date:
March 2011
Related Keywords:
- Renal Cell Carcinoma
- Biomarkers
- Prognosis response to treatment
- Renal cancer
- Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
Name | Location |
|---|
